Insulin-like Growth Factor Binding Protein-2 Level is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Sep 27

PMID 24069370

Citations 24

Authors

Chengcheng Guo

Haibo Lu

Wen Gao

Li Wang

Kaihua Lu

Shuhong Wu

Apar Pataer

Maosheng Huang

Randa El-Zein

Tongyu Lin

Jack A Roth

Reza Mehran

Wayne Hofstetter

Stephen G Swisher

Xifeng Wu

Bingliang Fang

Affiliations

Soon will be listed here.

Abstract

Background: We recently showed that IGFBP2 is overexpressed in primary lung cancer tissues. This study aims to determine whether IGFBP2 is elevated in blood samples of lung cancer patients and whether its level is associated with clinical outcomes.

Methodology/principal Findings: Plasma IGFBP2 levels were determined blindly by enzyme-linked immunosorbent assay in 80 lung cancer patients and 80 case-matched healthy controls for comparison. We analyzed blood samples for IGFBP2 levels from an additional 84 patients with lung cancer and then tested for associations between blood IGFBP2 levels and clinical parameters in all 164 lung cancer patients. All statistical tests were two-sided and differences with p<0.05 were considered significant. The mean plasma concentration of IGFBP2 in lung cancer patients was significantly higher than that in healthy controls (388.12 ± 261.00 ng/ml vs 219.30 ± 172.84 ng/ml, p<0.001). IGFBP2 was increased in all types of lung cancer, including adenocarcinoma, squamous cell cancer, and small-cell cancer, regardless of patients' age, sex, or smoking status. IGFBP2 levels were mildly but significantly associated with tumor size and were significantly higher in stage IV than stage I or III disease. A multivariate analysis showed that lung cancer patients whose blood IGFBP2 was higher than 160.9 ng/ml had a poor survival outcome, with a hazard ratio of 8.76 (95% CI 1.12-68.34, p=0.038 after adjustment for tumor size, pathology, and stage). The median survival time for patients with blood IGFBP2 >160.9 ng/ml is 15.1 months; whereas median survival time was 128.2 months for the patients whose blood IGFBP2 was ≤ 160.9 ng/ml (p =0.0002).

Conclusions/significance: Blood IGFBP2 is significantly increased in lung cancer patients. A high circulating level of IGFBP2 is significantly associated with poor survival, suggesting that blood IGFBP2 levels could be a prognostic biomarker for lung cancer.

Citing Articles

Integration of Gastric Cancer RNA-Seq Datasets Along With PPI Network Suggests That Nonhub Nodes Have the Potential to Become Biomarkers.

Siavoshi A, Piran M, Sharifi-Zarchi A, Ataellahi F Cancer Rep (Hoboken). 2025; 8(1):e70126.

PMID: 39854135 PMC: 11757912. DOI: 10.1002/cnr2.70126.

Mechanisms Underlying the Rarity of Skeletal Muscle Cancers.

Kump D Int J Mol Sci. 2024; 25(12).

PMID: 38928185 PMC: 11204341. DOI: 10.3390/ijms25126480.

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer.

Lu H, Ai J, Zheng Y, Zhou W, Zhang L, Zhu J Cell Death Dis. 2024; 15(6):447.

PMID: 38918360 PMC: 11199710. DOI: 10.1038/s41419-024-06843-y.

Transformer for Gene Expression Modeling (T-GEM): An Interpretable Deep Learning Model for Gene Expression-Based Phenotype Predictions.

Zhang T, Hasib M, Chiu Y, Han Z, Jin Y, Flores M Cancers (Basel). 2022; 14(19).

PMID: 36230685 PMC: 9562172. DOI: 10.3390/cancers14194763.

Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysis.

Zhang B, Hong C, Luo Y, Wei L, Luo Y, Peng Y Cancer Med. 2022; 11(16):3035-3047.

PMID: 35546443 PMC: 9385590. DOI: 10.1002/cam4.4680.

References

Baron-Hay S, Boyle F, Ferrier A, Scott C . Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res. 2004; 10(5):1796-806. DOI: 10.1158/1078-0432.ccr-0672-2. View

BAXTER R . Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000; 278(6):E967-76. DOI: 10.1152/ajpendo.2000.278.6.E967. View

Zhang Y, Ying X, Han S, Wang J, Zhou X, Bai E . Autoantibodies against insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol. 2012; 42(1):93-100. PMC: 3583617. DOI: 10.3892/ijo.2012.1699. View

Inman B, Harel F, Audet J, Meyer F, Douville P, Fradet Y . Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol. 2005; 47(5):695-702. DOI: 10.1016/j.eururo.2004.12.015. View

Ambrosini-Spaltro A, Farnedi A, Montironi R, Foschini M . IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma. Appl Immunohistochem Mol Morphol. 2011; 19(4):318-28. DOI: 10.1097/PAI.0b013e3128052936. View

Becher O, Peterson K, Khatua S, Santi M, MacDonald T . IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol. 2008; 23(10):1205-13. PMC: 3674842. DOI: 10.1177/0883073808321766. View

Cohen P, Peehl D, Stamey T, Wilson K, Clemmons D, Rosenfeld R . Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993; 76(4):1031-5. DOI: 10.1210/jcem.76.4.7682560. View

Salgia R . Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer. 2011; 117(17):3889-99. PMC: 3160199. DOI: 10.1002/cncr.25935. View

Clemmons D, Snyder D, Busby Jr W . Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab. 1991; 73(4):727-33. DOI: 10.1210/jcem-73-4-727. View

10.

Schneider J . Tumor markers in detection of lung cancer. Adv Clin Chem. 2006; 42:1-41. DOI: 10.1016/s0065-2423(06)42001-1. View

11.

Mishra L, Bass B, Ooi B, Sidawy A, Korman L . Role of insulin-like growth factor-I (IGF-I) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res. 2000; 8(6):473-9. DOI: 10.1016/s1096-6374(98)80300-6. View

12.

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

13.

Lancaster J, Sayer R, Blanchette C, Calingaert B, Konidari I, Gray J . High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006; 16(4):1529-35. DOI: 10.1111/j.1525-1438.2006.00623.x. View

14.

Matuschek C, Rudoy M, Peiper M, Gerber P, Hoff N, Buhren B . Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res. 2011; 16(10):451-6. PMC: 3400976. DOI: 10.1186/2047-783x-16-10-451. View

15.

Ladd J, Busald T, Johnson M, Zhang Q, Pitteri S, Wang H . Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila). 2012; 5(4):655-64. PMC: 3419141. DOI: 10.1158/1940-6207.CAPR-11-0412. View

16.

Holdenrieder S, Nagel D, Stieber P . Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomark. 2010; 6(3-4):179-90. DOI: 10.3233/CBM-2009-0128. View

17.

Ho P, BAXTER R . Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf). 1997; 46(3):333-42. View

18.

Patz Jr E, Campa M, Gottlin E, Kusmartseva I, Guan X, Herndon 2nd J . Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007; 25(35):5578-83. DOI: 10.1200/JCO.2007.13.5392. View

19.

Holmes K, Annala M, Chua C, Dunlap S, Liu Y, Hugen N . Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad Sci U S A. 2012; 109(9):3475-80. PMC: 3295320. DOI: 10.1073/pnas.1120375109. View

20.

Moore L, Holmes K, Smith S, Wu Y, Tchougounova E, Uhrbom L . IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Proc Natl Acad Sci U S A. 2009; 106(39):16675-9. PMC: 2757856. DOI: 10.1073/pnas.0900807106. View